Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 35 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALH | $4.4B | 39.9× | 10.5× | 2.6× | 13.3% | 37.6% | 6.0% | 26.0% | 26.0% | -0.3× | 24 |
| ACLS | $3.5B | 29.5× | 24.2× | 4.1× | -17.6% | 44.9% | 14.3% | 11.6% | 11.6% | -1.1× | 78 |
| ACMR | $3.4B | 36.0× | 23.6× | 3.8× | 15.2% | 44.4% | 10.4% | 6.4% | 5.5% | -4.1× | 72 |
| NATL | $3.4B | 21.4× | 7.5× | 0.8× | 1.1% | — | 3.7% | 40.2% | 5.1% | 3.0× | 73 |
| HAYW | $3.2B | 22.9× | 15.2× | 2.9× | 6.7% | 48.0% | 13.5% | 9.5% | 5.9% | 2.5× | 58 |
| KAI | $3.2B | 31.4× | 16.6× | 3.0× | -0.1% | 45.2% | 9.7% | 10.4% | 7.5% | 1.2× | 66 |
| CECO | $3.2B | 39.9× | 25.9× | 4.1× | 38.8% | 34.8% | 6.5% | 15.8% | 9.4% | 1.4× | 60 |
| EXTR | $3.1B | 76.1× | 39.1× | 2.4× | 12.6% | 61.5% | 3.3% | 47.5% | 16.7% | -0.6× | 58 |
| SXI | $3.0B | 28.6× | 14.6× | 3.4× | 12.8% | 41.7% | 11.7% | 13.9% | 8.2% | 1.5× | 63 |
| DNOW | $3.0B | — | — | 1.1× | 18.8% | 17.0% | -3.2% | -4.0% | -3.4% | — | 60 |
| DGII | $2.9B | 71.9× | 34.2× | 6.8× | 1.5% | 62.9% | 9.5% | 6.4% | 5.1% | 1.5× | 63 |
| VECO | $2.6B | 72.5× | 48.1× | 3.9× | -7.4% | 40.0% | 5.3% | 4.0% | 3.2% | 1.1× | 55 |
| OUST | $2.3B | — | — | 13.7× | 52.5% | 49.3% | -35.6% | -23.1% | -23.1% | — | 63 |
| KMT | $2.3B | 6.8× | 3.6× | 1.0× | 19.8% | 41.2% | 14.5% | 21.8% | 21.8% | -0.2× | 70 |
| CHRN | $2.3B | — | 99.3× | 31.8× | 459% | -23.9% | -70.3% | -28.0% | -27.4% | -0.3× | — |
| INVX | $2.1B | 25.0× | 10.8× | 2.1× | 48.0% | 31.0% | 8.5% | 7.9% | 7.9% | 0.0× | 42 |
| EPAC | $2.0B | 23.2× | 13.8× | 3.3× | 4.6% | 50.5% | 15.0% | 21.4% | 14.9% | 0.3× | 50 |
| DBD | $2.0B | 23.3× | 7.0× | 0.5× | 1.5% | 25.3% | 2.5% | 8.6% | 4.6% | 1.5× | 33 |
| GRC | $2.0B | 36.8× | 18.2× | 2.9× | 3.4% | 30.6% | 7.8% | 12.8% | 7.3% | 2.2× | 51 |
| ATEN | $1.9B | 45.3× | 32.6× | 6.5× | 11.0% | 79.3% | 14.5% | 19.9% | 9.8% | 2.4× | 51 |
| AZTA | $1.8B | — | — | 3.0× | 3.6% | 45.5% | -9.4% | -3.2% | -3.2% | — | 47 |
| ALG | $1.8B | 17.1× | 8.3× | 1.1× | -1.5% | 24.8% | 6.5% | 9.0% | 9.0% | -1.7× | 56 |
| OMCL | $1.7B | — | 17.6× | 1.4× | 6.5% | 42.5% | 0.2% | 0.2% | 0.2% | -2.3× | 47 |
| CRSR | $1.5B | — | 94.1× | 1.0× | 11.9% | 28.9% | -1.1% | -2.6% | -2.1% | 1.5× | 38 |
| CRCT | $1.3B | 17.7× | 8.6× | 1.8× | -0.5% | 55.1% | 10.8% | 22.3% | 22.3% | -2.1× | 21 |
Peers = companies sharing AZTA's sector (Special Industry Machinery, NEC) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $38.3M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -3%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
EOD close · as of 2026-10-29
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.8M 100.0% | $573.4M 100.0% | $551.5M 100.0% | $555.5M 100.0% | $513.7M 100.0% | $388.5M 100.0% | $334.2M 100.0% | $631.6M 100.0% | $527.5M 100.0% | $434.0M 100.0% |
| Cost of Revenue | $323.5M 54.5% | $318.8M 55.6% | $312.3M 56.6% | $299.9M 54.0% | $269.9M 52.5% | $216.4M 55.7% | $199.6M 59.7% | $385.5M 61.0% | $425.5M 80.7% | $362.2M 83.5% |
| Cost of Products | — | — | — | — | — | — | — | $288.3M 45.7% | $249.4M 47.3% | $212.0M 48.9% |
| Cost of Services | — | — | — | — | — | — | — | $97.2M 15.4% | $79.2M 15.0% | $65.3M 15.0% |
| Gross Profit | $270.3M 45.5% | $254.6M 44.4% | $239.2M 43.4% | $255.6M 46.0% | $243.8M 47.5% | $172.1M 44.3% | $134.6M 40.3% | $246.1M 39.0% | $198.9M 37.7% | $156.7M 36.1% |
| Research & Development | $30.4M 5.1% | $31.5M 5.5% | $32.1M 5.8% | $27.5M 5.0% | $22.4M 4.4% | $17.8M 4.6% | $17.3M 5.2% | $46.9M 7.4% | $39.9M 7.6% | $44.2M 10.2% |
| Selling, General & Admin | $261.6M 44.0% | $263.0M 45.9% | $263.7M 47.8% | $251.5M 45.3% | $252.1M 49.1% | $190.3M 49.0% | $163.3M 48.9% | $167.0M 26.4% | $141.5M 26.8% | $119.3M 27.5% |
| Total Operating Expenses | $297.1M 50.0% | $305.9M 53.3% | $300.5M 54.5% | $280.3M 50.5% | $274.9M 53.5% | $208.7M 53.7% | $182.0M 54.5% | $214.7M 34.0% | $184.6M 35.0% | $173.7M 40.0% |
| Operating Income | -$26.8M -4.5% | -$51.3M -8.9% | -$61.2M -11.1% | -$24.7M -4.5% | -$31.1M -6.1% | -$36.6M -9.4% | -$47.4M -14.2% | $31.4M 5.0% | $14.3M 2.7% | -$17.1M -3.9% |
| Interest Expense | — | — | — | $4.6M 0.8% | $2.0M 0.4% | $2.9M 0.8% | $22.3M 6.7% | $9.5M 1.5% | $408K 0.1% | $157K 0.0% |
| Interest & Investment Income | — | $33.2M 5.8% | $43.7M 7.9% | $15.7M 2.8% | — | — | — | — | — | $452K 0.1% |
| Other Income (Expense), net | $922K 0.2% | -$732K -0.1% | -$2.3M -0.4% | -$898K -0.2% | -$16.5M -3.2% | -$1.6M -0.4% | -$1.4M -0.4% | -$3.3M -0.5% | -$1.7M -0.3% | -$1.4M -0.3% |
| Pretax Income | -$7.1M -1.2% | -$19.1M -3.3% | -$20.0M -3.6% | -$9.9M -1.8% | -$49.0M -9.5% | -$40.3M -10.4% | -$84.0M -25.1% | $20.5M 3.2% | $14.5M 2.8% | -$18.1M -4.2% |
| Income Tax Expense | -$31.6M -5.3% | $5.2M 0.9% | -$12.0M -2.2% | $1.4M 0.2% | -$20.1M -3.9% | -$13.9M -3.6% | -$22.8M -6.8% | -$47.3M -7.5% | $3.4M 0.6% | $66.3M 15.3% |
| Net Income | -$55.8M -9.4% | -$164.9M -28.8% | -$14.6M -2.7% | $2.13B 384.0% | $110.7M 21.6% | $64.9M 16.7% | $437.4M 130.9% | $116.6M 18.5% | $62.6M 11.9% | -$69.5M -16.0% |
| Per Share | ||||||||||
| EPS (Basic) | -$1.22 | -$3.10 | -$0.22 | $28.48 | $1.49 | $0.88 | $6.08 | $1.65 | $0.90 | -$1.01 |
| EPS (Diluted) | -$1.22 | -$3.10 | -$0.22 | $28.48 | $1.49 | $0.88 | $6.04 | $1.64 | $0.89 | -$1.01 |
| Weighted Avg Shares (Basic) | 45.7M | 53.2M | 66.3M | 74.9M | 74.2M | 73.6M | 72.0M | 70.5M | 69.6M | 68.5M |
| Weighted Avg Shares (Diluted) | 45.9M | 53.2M | 66.3M | 74.9M | 74.5M | 73.8M | 72.4M | 70.9M | 70.5M | 68.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 2 positive fiscal years (FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $41.27 today, the market must believe free cash flow compounds 24.1%/yr for a decade (off $25.3M on the 3-yr avg basis).
On the basis ($7.7M) the requirement is 41.6%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 24.1% is more optimistic than its 9-yr track record.
Default is 10.6% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.04B shares (market data) · net debt -$279.8M
mean -58.8% · volatility σ 319% · implied rate exceeded in 2/6 yrs
Central path = implied 24.1%/yr growth; shaded band = ±1σ (319%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $279.8M (at 2025-09-30) covers all $50.4M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2020-03-31 (10-Q). The cash figure is from 2025-09-30, so the two are not the same balance-sheet date — the schedule has not been refiled since.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Interest last disclosed in FY2022 (no longer broken out).
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-22 | Madaus Martin D Interim CEO | Tax withholding | 1,294 | $36.01 | $47k |
| 2026-09-22 | Madaus Martin D Interim CEO | Tax withholding | 1,456 | $34.28 | $50k |
| 2026-09-15 | Bello Erik J. VP Chief Accounting Officer | Grant | 4,586 | $0.00 | $0 |
| 2026-09-14 | Madaus Martin D Interim CEO | Grant | 36,653 | $0.00 | $0 |
| 2026-09-14 |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| Grant |
| 15,272 |
| $0.00 |
| $0 |
| 2026-09-14 | Pirogova Olga SVP and CHRO | Grant | 15,272 | $0.00 | $0 |
| 2026-09-14 | Lin Lawrence Y. EVP, CFO and Treasurer | Grant | 30,544 | $0.00 | $0 |
| 2026-09-14 | Starr Ephraim SVP, Gen Counsel & Secretary | Grant | 15,272 | $0.00 | $0 |
| 2026-08-09 | Pirogova Olga SVP and CHRO | Tax withholding | 1,085 | $32.04 | $35k |
| 2026-07-31 | Starr Ephraim SVP, Gen Counsel & Secretary | Plan purchase | 335 | $24.17 | $8k |
| 2026-05-18 | Cornog William L Director | Open-market buyindirect | 10,000 | $16.38 | $164k |
| 2026-05-15 | Starr Ephraim SVP, Gen Counsel & Secretary | Tax withholding | 3,621 | $16.02 | $58k |
| 2026-04-28 | Martin William E. Iii President Multiomics | Grant | 17,790 | $24.24 | $431k |
| 2026-02-06 | Nova Tina Susan Director | Grant | 5,663 | $27.85 | $158k |
| 2026-02-05 | Koffey Quentin Director | Grant91d late | 5,663 | $0.00 | $0 |
| 2026-02-05 | Madaus Martin D Director | Grant | 5,663 | — | — |
| 2026-02-05 | Doshi Dipal Director | Grant | 5,663 | $27.85 | $158k |
| 2026-02-05 | Casal Frank Director | Grant | 7,243 | $27.85 | $202k |
| 2026-02-05 | Mclaughlin Erica Director | Grant | 5,663 | $27.85 | $158k |
| 2026-02-05 | Davis Robyn C Director | Grant | 5,663 | — | — |
| 2025-11-24 | Marotta John President and CEO | Grant4d late | 118,194 | $0.00 | $0 |
| 2025-11-24 | Lin Lawrence Y. EVP, CFO and Treasurer | Grant | 36,681 | $0.00 | $0 |
| 2025-11-24 | Pirogova Olga SVP and CHRO | Grant | 16,303 | $0.00 | $0 |
| 2025-11-24 | Zhou Ginger SVP and GM, Multiomics | Grant | 13,042 | $0.00 | $0 |
| 2025-11-24 | Starr Ephraim SVP, Gen Counsel & Secretary | Grant | 34,235 | $0.00 | $0 |
| 2025-11-14 | Zhou Ginger SVP and GM, Multiomics | Tax withholding | 1,118 | $29.75 | $33k |
| 2025-11-14 | Pirogova Olga SVP and CHRO | Tax withholding | 1,553 | $29.75 | $46k |
| 2025-11-14 | Lin Lawrence Y. EVP, CFO and Treasurer | Tax withholding | 3,039 | $29.75 | $90k |
| 2025-11-14 | Marotta John President and CEO | Tax withholding | 10,980 | $29.75 | $327k |
EOD close · as of 2026-10-29
Where each multiple sits in its own 14-yr range · 60th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -3% against ROIC -3% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 61.0 | 59.7 | 55.7 | 52.5 | 54.0 | 56.6 | 55.6 | 54.5 |
| Gross Profit | 39.0 | 40.3 | 44.3 | 47.5 | 46.0 | 43.4 | 44.4 | 45.5 |
| R&D | 7.4 | 5.2 | 4.6 | 4.4 | 5.0 | 5.8 | 5.5 | 5.1 |
| SG&A | 26.4 | 48.9 | 49.0 | 49.1 | 45.3 | 47.8 | 45.9 | 44.0 |
| Operating Income | 5.0 | -14.2 | -9.4 | -6.1 | -4.5 | -11.1 | -8.9 | -4.5 |
| Income Tax | -7.5 | -6.8 | -3.6 | -3.9 | 0.2 | -2.2 | 0.9 | -5.3 |
| Net Income | 18.5 | 130.9 | 16.7 | 21.6 | 384.0 | -2.7 | -28.8 | -9.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on AZTA: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
No positive operating income in the last three years, so there is no return on capital to compare against its cost.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 36.1% | -3.9% | -16.0% |
| FY2017 | 37.7% | 2.7% | 11.9% |
| FY2018 | 39.0% | 5.0% | 18.5% |
| FY2019 | 40.3% | -14.2% | 130.9% |
| FY2020 | 44.3% | -9.4% | 16.7% |
| FY2021 | 47.5% | -6.1% | 21.6% |
| FY2022 | 46.0% | -4.5% | 384.0% |
| FY2023 | 43.4% | -11.1% | -2.7% |
| FY2024 | 44.4% | -8.9% | -28.8% |
| FY2025 | 45.5% | -4.5% | -9.4% |
Return on equity (-3%) and return on invested capital (-3%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Cash conversion of 0.19x sits below the level that would make the earnings clearly cash-backed.
Reported free cash flow is $38M; after share-based compensation it is $17M. The difference is a real cost that the cash flow statement adds back.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
This schedule comes from a filing dated 2020-03-31, 2404 days old. Maturities are shown relative to that date, not to today.
Ladder as of 2020-03-31 (10-Q); cash from the 2025-09-30 balance sheet; FCF from FY2025.
Balance sheet at 2025-09-30. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: interest_expense.
At $41.27, free cash flow must compound 24.69%/yr for 10 years. It has done -8.9%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | −103.1% | 24.7% |
| FY2022 | −655.9% | 24.7% |
| FY2025 | 210.3% | 24.7% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 1 of the last 3 years.
| Step | Amount | Running total |
|---|---|---|
| Net income | −$56M | −$56M |
| Share-based comp | $21M | −$35M |
| Other non-cash & working capital | $107M | $72M |
| Operating cash flow | $72M | $72M |
| Capex | −$34M | $38M |
| Free cash flow | $38M | $38M |
| FCF after SBC | $17M | $17M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 16.3% | -42.8% | -59.0 points |
| FY2021 | 32.2% | 26.5% | -5.8 points |
| FY2022 | 8.1% | 36.6% | 28.5 points |
| FY2023 | -0.7% | -4.4% | -3.7 points |
| FY2024 | 4.0% | -1.5% | -5.5 points |
| FY2025 | 3.5% | -7.8% | -11.3 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 180.9 days | 181.9 days | 107.8 days | 255 days |
| FY2020 | 89 days | 62.6 days | 43.3 days | 108.3 days |
| FY2021 | 85.2 days | 81.7 days | 57.3 days | 109.6 days |
| FY2022 | 107.6 days | 104.1 days | 47 days | 164.7 days |
| FY2023 | 103.6 days | 149.8 days | 41.8 days | 211.6 days |
| FY2024 | 98.1 days | 81.6 days | 38.2 days | 141.6 days |
| FY2025 | 87.4 days | 84.6 days | 42.6 days | 129.4 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | 22.9 percent |
| FY2020 | 1.7 percent |
| FY2021 | -2.1 percent |
| FY2022 | 69.9 percent |
| FY2023 | -0.7 percent |
| FY2024 | -10.2 percent |
| FY2025 | -6.2 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.